In a February 4, 2022 news release Valneva/Pfizer reported positive Phase 2 data findings for their Lyme disease vaccine candidate, VLA15. According to the news release, findings of the Phase 2 trial show there is value in adding a third dose of vaccine. In the Phase 2 clinical trial, researchers found a stronger immune response in adult participants who received three doses versus two doses of VLA15. The induction of anti-OspA IgG (anti-outer surface protein A immunoglobulin G) antibody titers was found to be higher in trial participants who received the three-dose primary series compared to those who received the two-dose primary series. The three-dose regimen provides the VLA15 second dose at two months and the VLA15 third dose at six months.
The Phase 2 clinical trial for pediatrics (aged 5-17) is ongoing with initial data results expected to be released in summer 2022. Valneva/Pfizer plans to evaluate the three-dose VLA15 regimen in a Phase 3 clinical trial in both adult and pediatric study participants beginning fall of 2022, subject to regulatory approval.
Read the full Valneva Press release here
For more information on the Valneva Lyme vaccine history:
Read LDA Article: Phase 2 Study for Lyme Disease Vaccine Candidate Begins
Read LDA Article: Lyme Vaccine Candidate: Valneva Announces Phase 2 Study Results
Read LDA Article: Lyme Disease Vaccine Collaboration Announced
Read LDA Article/Watch: Fox 5 NY News Special on Lyme & on Lyme Vaccine, Friday 9/7 at 10:30PM
Read LDA Article: New Lyme Vaccine in Clinical Trials: Update!
For information on the first Lyme vaccine, LymeRix–withdrawn from market:
Read LDA Articles: LymeRix articles 1
Read LDA Articles: LymeRix articles 2